Yahoo Finance

AtaiBeckley targets Q2 start for Phase 3 depression trial as pipeline advances

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
STAT

Oral ketamine tablets effective for treating depression, new study finds

The results of a randomized controlled trial published Monday showed oral ketamine tablets were safe and effective for patients with treatment-resistant depression — the latest attempt by researchers ...
Nasdaq

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

SALT LAKE CITY, June 26, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective ...

Lipocine Showcases Phase 3 Data in Postpartum Depression

Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter The latest announcement is out from Lipocine ( (LPCN)). On May 26, 2026, Lipocine ...
MarketBeat on MSN

Compass Pathways eyes Q4 FDA filing for psilocybin depression drug after phase 3 wins

Key Points Interested in Compass Pathways PLC Sponsored ADR? Here are five stocks we like better. Compass Pathways said it ...

Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that its Phase 3 ...
Medscape

Esketamine Monotherapy Safe, Effective for Resistant Depression: Phase 4 Data

Esketamine monotherapy was associated with significantly alleviated symptoms of treatment-resistant depression (TRD) at day 28 compared to placebo in a new phase 4 trial. The research extends findings ...
MedPage Today

Novel Agent for Major Depression Moves to Phase III, Even With Setback

For patients with major depression, there was a clinically meaningful but not statistically significant improvement in the primary endpoint with 20-mg azetukalner. There were significant improvements ...
FierceBiotech

J&J's daily add-on pill improves depression and insomnia symptoms, acing phase 3

Johnson & Johnson’s oral add-on drug significantly improved depressive symptoms and sleep outcomes in a phase 3 trial for patients who previously did not benefit from antidepressants alone. The ...
MarketBeat on MSN

Definium Therapeutics eyes key DT-120 depression data, advances anxiety program

Definium Therapeutics (NASDAQ:DFTX) Chief Financial Officer Brandi Roberts said the company is preparing for several key ...
Nasdaq

atai Life Sciences Doses First Patient in Phase 2 Elumina Trial for VLS-01 in Treatment-Resistant Depression

atai Life Sciences initiates Phase 2 trial for VLS-01, a treatment for treatment-resistant depression, with results expected in 2026. Atai Life Sciences has initiated the Phase 2 Elumina trial to ...